Abstract：【Objective】 To investigate the changes and clinical significance of serum mir-198 and mir-744 expression in patients with gastric cancer. 【Methods】 From January 2016 to December 2018, 106 gastric cancer patients admitted to our hospital were selected as the study object (observation group), and 35 subjects with normal physical examination in our hospital during the same period were selected as the control group. The qRT PCR was used to detect the expression of mir-198 and mir-744. The expression levels of mir-198 and mir-744 in serum of the two groups were compared, and the relationship between them and the clinicopathology of gastric cancer patients was analyzed. The diagnostic efficacy of the expression levels of mir-198 and mir-744 in serum for gastric cancer was analyzed by ROC curve.【Results】 The serum mir-198,mir-744 expression level of the observation group was significantly higher than that of the control group, and the serum mir-198,mir-744 expression levels of patients with stage Ⅲ/Ⅳ, invasion of serosa and high/median differentiation of the serum mir-198,mir-744 expression levels were significantly higher in the observation group than those in stage Ⅰ/Ⅱ, non-invasive serosa and low or undifferentiated patients, respectively, and the differences were statistically significant (P<0.05). ROC curve analysis showed that the lower AUC area of serum mir-198 for the diagnosis of gastric cancer was 0.863, the critical value was 3.93, the sensitivity was 76.42% and the specificity was 88.57%. the lower AUC area of serum mir-744 for the diagnosis of gastric cancer was 0.806, the critical value was 2.48, the sensitivity was 78.30% and the specificity was 77.14%. There was no significant difference in diagnostic efficacy (Z=1.056, P=0.291).【Conclusion】 Mir-198 and mir-744 are highly expressed in the serum of patients with gastric cancer, which are related to the clinical stage, infiltration depth and differentiation degree of patients. They can be used as potential molecular markers for diagnosis and treatment of gastric cancer.
张华. 胃癌患者血清mir-198、mir-744表达水平的变化及临床意义[J]. 医学临床研究, 2020, 37(5): 730-732.
ZHANG Hua. Changes and Clinical Significance of Serum mir-198 and mir-744 Expression in Patients with Gastric Cancer. JOURNAL OF CLINICAL RESEARCH, 2020, 37(5): 730-732.
[1] 刘辉,张靖,朱金水. microRNA与胃癌相关信号通路调控的研究进展[J].国际消化病杂志,2017,37(06):361-365. [2] Yue Zhang, Dong-Hui Guan, Rong-Xiu Bi, et al .Prognostic value of microRNAs in gastric cancer: a meta-analysis[J].Oncotarget,2017 ,8(33): 55489-55510. [3] 徐晨光,谢娟,龙志,等. 血液循环和胃液中的微RNA在胃癌诊断中的应用价值[J].国际消化病杂志,2018,38(05):287-289+319. [4] Zhu XL, Ren LF, Wang HP, et al .Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer[J].World J Gastroenterol,2019,25(13):1580-1591. [5] 路玉盼,董宪喆,王瑾,等. microRNAs调控胃癌相关基因的研究进展[J].中国药理学通报,2018,34(11):1481-1485. [6] 朱利红,段树鹏,秦海霞,等. miR-198靶向MAPK1调控宫颈癌HeLa细胞增殖、凋亡和侵袭[J].肿瘤防治研究,2018,45(12):959-964. [7] Minglei Zhang, Hai Li, Yun Zhang,et al .Oncogenic miR-744 promotes prostate cancer growth through direct targeting of LKB1[J].Oncol Lett,2019 ,17(2): 2257-2265. [8] 左婷婷,郑荣寿,曾红梅,等. 中国胃癌流行病学现状[J].中国肿瘤临床,2017,44(01):52-58. [9] 刘曙正,曹小琴,于亮,等. 2003～2012年林州市胃癌发病、生存及患病分析[J].中国肿瘤,2018,27(03):181-185. [10] 黄莎,戴瑨,高娟娟,等. 胃癌分子流行病学研究进展[J].中国肿瘤临床,2019,46(01):16-21. [11] 邵建斌,杨梅兰. miR-198靶向MAPK1对人乳腺癌MCF-7细胞增殖和凋亡的调控作用[J].中国肿瘤生物治疗杂志,2018,25(12):1259-1263. [12] Pereira AL, Magalh es L, Moreira FC, et al .Epigenetic Field Cancerization in Gastric Cancer: microRNAs as Promising Biomarkers[J].J Cancer,2019 ,10(6):1560-1569. [13] 吴学朕,刘露,王春晖,等. 胰腺癌患者血浆miR-744表达及临床意义[J].热带医学杂志,2016,16(05):597-599+621. [14] Jixiang Liu, Yanlei Wei, Shouyong Li, et al .MicroRNA-744 promotes cell apoptosis via targeting B cell lymphoma-2 in gastric cancer cell line SGC-7901[J].Exp Ther Med,2018,16(4): 3611-3616. [15] 王套瑞, 李珉珉. 新型胃癌相关循环肿瘤标志物的临床应用[J].临床检验杂志, 2016, 34(9):679-681.
2020, Vol. 37 
